<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140611018063N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-09-03</date_registration>
      <primary_sponsor>Birjand University of Medical Sciences</primary_sponsor>
      <public_title>Diclofenac vs. Pethidine in cholecystectomy pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effect of Diclofenac and Pethidine on the severity of the Postoperative Pain of Laparoscopic Cholecystectomy in Opiate-Dependent and Non-Dependent Patients.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2015-11-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/39512</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: 60 packed packs including 30 packs with a paper with letter “A” written on it and 30 packs with a paper with letter “B” written on it will be generated. Letter “A” represents the group receiving pethidine and letter “B” represents the group receiving diclofenac. Using block randomization and packed envelopes, the opioid dependent group will be divided randomly and equally into two groups: one will receive diclofenac and the other will receive pethidine. By block randomization and packed envelopes, the non-opioid dependent group will be divided randomly and equally into two groups: one group will receive diclofenac and the other group will receive pethidine. , Blinding description: A nurse who does not know the prescribed drug uses the Verbal Rating Scale to evaluates the severity of pain in the patients.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: pain. Condition 2: Cholelithiasis. Condition 3: Acute cholecystitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: One subset of opioid-dependent patients will be given 100 mg Diclofenac suppository through the rectal starting from 1 hour after the recovery and repeated every 6 hours until 24 hours;. Intervention 2: Intervention group: One subset of opioid-independent patients will be given 100 mg Diclofenac suppository through the rectal starting from 1 hour after the recovery and repeated every 6 hours until 24 hours;. Intervention 3: Intervention group: one subset of opioid-dependent patients will be given 25 mg pethidine injection intravenously starting from 1 hour after the recovery and repeated every 6 hours until 24 hours;. Intervention 4: Intervention group: one subset of opioid-independent patients will be given 25 mg pethidine injection intravenously starting from 1 hour after the recovery and repeated every 6 hours until 24 hours.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The entire statistical data from this study can be shared as needed based on the ethics committee's criteria.

When:
The results of this study, after publishing the results as a paper, will be published and shared.

To whom:
The data from this study will be available to all researchers.

Conditions:
All academic researchers, in the form of research projects approved by the Ethics Committee, are allowed to access the data and perform the necessary analyzes on the documentation of this research.

Where to obtain:
Applicants for obtaining documentation of this study can request information by email with the corresponding author.

How to obtain:
Researchers should send the research proposal code and ethics committee registrant code with the applicant email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Rajabpour-Sanati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>NO. 37, 13th Modarres</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9717911766</zip>
        <telephone>+98 56 3234 1067</telephone>
        <email>ali.poursanati@gmail.com</email>
        <affiliation>Birjand University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mohammad Yarani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Moallem Blvd.</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9717853577</zip>
        <telephone>+98 56 3239 5000</telephone>
        <email>mohammadyarani@bums.ac.ir</email>
        <affiliation>Birjand University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>patients with detected gallstones requiring surgery
patients with biliary sludge requiring surgery</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>history of laparoscopic cholecystectomy
severe obstructive pulmonary disease
congestive heart failure (EF &lt;20%)
acute cholecystitis
gangrenous
empyema gallbladder
intestinal fistula in the biliary tract
obesity
pregnancy
ventriculoperitoneal shunt
previous abdominal surgery
appearance of serious drug side effects
cirrhosis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R52.0</hc_code>
      <hc_code>K80</hc_code>
      <hc_code>K81.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute pain</hc_keyword>
      <hc_keyword>Cholelithiasis</hc_keyword>
      <hc_keyword>Acute cholecystitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: One subset of opioid-dependent patients will be given 100 mg Diclofenac suppository through the rectal starting from 1 hour after the recovery and repeated every 6 hours until 24 hours;</i_keyword>
      <i_keyword>Intervention group: One subset of opioid-independent patients will be given 100 mg Diclofenac suppository through the rectal starting from 1 hour after the recovery and repeated every 6 hours until 24 hours;</i_keyword>
      <i_keyword>Intervention group: one subset of opioid-dependent patients will be given 25 mg pethidine injection intravenously starting from 1 hour after the recovery and repeated every 6 hours until 24 hours;</i_keyword>
      <i_keyword>Intervention group: one subset of opioid-independent patients will be given 25 mg pethidine injection intravenously starting from 1 hour after the recovery and repeated every 6 hours until 24 hours.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The effect of prescribed drug on the severity of pain. Timepoint: measuring severity of the pain before intervention, measuring severity of the pain 24 hours after the initiation of the anti-pain drug (pethidine or diclofenac). Method of measurement: verbal rating scale of pain.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Birjand University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-04-12</approval_date>
        <contact_name>Birjand University of Medical Sciences</contact_name>
        <contact_address>NO. 37, 13th Modarres Street Birjand South Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
